Medical News on Cancer
During Radiation Treatment For Prostate Cancer The Antioxidant Beta-Carotene Found To Be Safe
Jun 05, 2012
Despite past safety concerns, the antioxidant supplement beta-carotene, is safe to use during radiation therapy treatments for prostate cancer and does not increase the risk of prostate cancer death or metastases, according to a study in the International Journal of Radiation Oncology-Biology-Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO)... Read More
Overcoming Drug Resistance In Cancer
Jun 05, 2012
Overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. Several drug therapies have been developed to treat these EGFR-associated cancers; however, many patients have developed resistance to these drugs and are therefore no longer responsive to drug treatment... Read More
Novel Combination Activates Two Key Genes Involved In Lung Cancer
Jun 05, 2012
A team of researchers led by Dr. Goutham Narla at Case Western Reserve University School of Medicine in collaboration with scientists at Mount Sinai School of Medicine in New York, have discovered a previously unrecognized signaling network disrupted in lung cancer that can be turned back on by a novel combination of two previously approved FDA drugs... Read More
Liver Metastases And Its Prognostic Significance In Men With Metastatic Prostate Cancer
Jun 01, 2012
Liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC), according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. (Abstract # 4655, Sunday, June 3, 8:00 AM - 12:00 PM CST, S Hall A2)... Read More
Mesothelioma - Photodynamic Therapy Yields Longer Survival Rates
Jun 01, 2012
Treating patients with malignant pleural mesothelioma with PDT (photodynamic therapy) alongside lung-sparing surgery appears to result in significantly longer survival rates - up to two years longer compared to other treatments, and sometimes even more, researchers from the Perelman School of Medicine, University of Pennsylvania reported in Annals of Thoracic Surgey... Read More
First Success Of Targeted Therapy In Type Of Non-Small Cell Lung Cancer
Jun 01, 2012
A novel compound has become the first targeted therapy to benefit patients with the most common genetic subtype of lung cancer, an international clinical trial led by scientists at Dana-Farber Cancer Institute and other institutions will report at the annual meeting of the American Society of Clinical Oncology (ASCO) June 1-5 in Chicago. Pasi A... Read More
Younger Colon Cancer Patients Have Worse Prognosis At Diagnosis, Yet Better Survival
Jun 01, 2012
Younger patients with colorectal cancer were more likely to present advanced stage tumors at diagnosis and metastasize much sooner, yet had better than or equal survival to patients 50 and older, according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago. (Abstract #3621, Monday, June 4, 8:00 AM - 12:00 PM CST, S Hall A2)... Read More
Men With Metastatic Hormone-Refractory Prostate Cancer Benefit From Cabazitaxel When Docetaxel Is No Longer An Option
May 31, 2012
Cabazitaxel (trade name: Jevtana®) has been approved since March 2011 in men with metastatic prostate cancer who no longer respond to conventional therapy with hormone blockers and have already been pre-treated with the cytostatic drug docetaxel... Read More
Earlier Detection Of Diseases Likely With New Super-Sensitive Tests
May 29, 2012
Scientists have developed an ultra-sensitive test that should enable them to detect signs of a disease in its earliest stages, in research published in the journal Nature Materials. The scientists, from Imperial College London and the University of Vigo, have created a test to detect particular molecules that indicate the presence of disease, even when these are in very low concentrations... Read More
Cancer-Promoting, Glucose-Processing Akt Activated By Skp2
May 29, 2012
HER2 and its epidermal growth factor receptor cousins mobilize a specialized protein to activate a major player in cancer development and sugar metabolism, scientists report in Cell. This chain of events, the scientists found, promotes Herceptin resistance in breast cancer and activation of glucose metabolism (glycolysis), which cancer cells primarily rely on to fuel their growth and survive... Read More
Previous Page Next Page